Palatin Technologies Inc
LSE:0KF3
Palatin Technologies Inc
LSE:0KF3
Price:
27.71
USD
110.72%
Market Closed
Market Cap:
$761.2B
Relative Value
The Relative Value of one
0KF3
stock under the Base Case scenario is
6.25
USD.
Compared to the current market price of 27.71 USD,
Palatin Technologies Inc
is
Overvalued by 77%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
0KF3
Relative Value
Base Case
6.25
USD
Overvaluation 77%
Multiples Across Competitors
0KF3 Competitors Multiples
Palatin Technologies Inc Competitors
Palatin Technologies Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Palatin Technologies Inc
LSE:0KF3
|
34m USD | 4.5 | -8.3 | -8 | -7.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
399.2B USD | 6.7 | 170 | 16.5 | 23.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
202.4B USD | 5.5 | 26.2 | 15 | 15 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
188.1B USD | 6.4 | 22.1 | 15 | 15 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121B USD | 10.1 | 30.6 | 23.4 | 24.4 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.1B USD | 5.7 | 18.3 | 13.8 | 15.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
74.2B AUD | 3.3 | 17.2 | 11.7 | 14.7 | |
| NL |
|
argenx SE
XBRU:ARGX
|
44.2B EUR | 14.2 | 33.5 | 57.5 | 59.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
